+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia



A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia



Leukemia and Lymphoma 42(3): 379-386



Fever is frequently the only clinical sign of infection in patients with chemo-induced neutropenia. In this setting, empirical administration of broad spectrum antibiotics must be rapid. The aim of this work was to compare, for the first time, cefpirome (CPO) and piperacillin-tazobactam (PT) in a large randomized trial. Two hundred-eight febrile neutropenic episodes (FNE) (> or = 38.5 degrees C and ANC < or = 0.5 giga/l) were treated by randomization, as first line therapy, using either CPO 2 g x 2/day (105 cases) or PT 4 g x 3/day (103 cases), alone (CPO: 15/PT: 15), or plus aminoglycoside (165 cases, CPO: 82/PT: 83) or quinolone (CPO: 2/PT: 2). There were 131 men and 77 women aged between 17 and 83 years (median: 49) who received chemotherapy (n = 160) or allogeneic (n = 10) or autologous (n = 38) stem cell transplantations. Underlying diseases were: acute leukemia (n = 131), lymphoma (n = 33), myeloma (n = 16), solid tumor (n = 8), myeloproliferative disorder (n = 9), chronic lymphoid leukemia (n = 5), aplastic anemia (n = 3), myelodysplasia (n = 3). Distribution of age, neutropenia duration (median: 17 days), underlying disease, and protocol therapy duration (median: 11 days) was comparable in both arms. A microbiologically documented infection (MDI) was evidenced in 57 cases (27%). Bacteria were isolated from blood cultures in 54 cases (Gram positive: 32 cases). Their in vitro susceptibility rates to CPO and PT were not different. Two days after antibiotics initiation, clinical (fever disappearance) and microbiological (culture negativation) success rates (SR) were 62% for CPO versus 61% for PT and 50% versus 55% respectively in case of MDI (p = 0.89). Two deaths and 77 failures were registered. At the end of protocol, SR (no antibiotic change/absence of superinfection) was 59% with CPO versus 50% with PT (p = 0.27) and 53% versus 40% respectively in the 151 cases with neutropenia > or = 10 days (p = 0.17). The occurrence of side effects was similar in both arms. In our hands, the efficacy of CPO and PT was comparable for treating FNE.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045102188

Download citation: RISBibTeXText

PMID: 11699402

DOI: 10.3109/10428190109064594


Related references

A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 267, 2001

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: Results of an open, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 50(1): 79-88, 2002

Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. International Journal of Hematology 79(1): 74-78, 2004

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology 28(4): 311-320, 2011

Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Japanese Journal of Clinical Oncology 40(8): 761-767, 2010

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Supportive Care in Cancer 13(6): 387-392, 2005

Ertapenem Versus Piperacillin/Tazobactam for Diabetic Foot Infections (SIDESTEP): Prospective, Randomized, Controlled, Double-blinded, Multicentre Trial. Yearbook of Medicine 2006: 95-97, 2006

Cefepime plus amikacin versus piperacillin/tazobactam plus amikacin for initial antibiotic therapy in hematological patients with febrile neutropenia Results of an open, randomized, multicenter trial. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 474, 2000

Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. European Journal of Clinical Microbiology and Infectious Diseases 29(4): 417-427, 2010

Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatric Hematology and Oncology 23(3): 177-186, 2006

Double-blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam vs piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 722, 1999

A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatric Blood and Cancer 51(6): 774-777, 2008

Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study. Pediatric Blood and Cancer 62(2): 356-358, 2015

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. Journal of Clinical Oncology 32(14): 1463-1471, 2014

Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors. Pediatric Hematology and Oncology 30(2): 141-148, 2013